Alexander Schuth Sells 2,857 Shares of Denali Therapeutics (NASDAQ:DNLI) Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Alexander Schuth sold 2,857 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the transaction, the insider directly owned 281,763 shares in the company, valued at approximately $7,063,798.41. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $24.40 on Friday. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01. Denali Therapeutics Inc. has a 52-week low of $12.58 and a 52-week high of $27.30. The company has a 50-day simple moving average of $24.04 and a 200-day simple moving average of $21.48. The company has a market capitalization of $3.90 billion, a PE ratio of -8.59 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million for the quarter, compared to analysts’ expectations of $2.15 million. During the same quarter in the prior year, the company posted ($0.72) earnings per share. Equities research analysts predict that Denali Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

DNLI has been the subject of several research analyst reports. Leerink Partners dropped their price objective on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, April 22nd. Wall Street Zen upgraded Denali Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. BTIG Research reissued a “buy” rating and issued a $39.00 target price on shares of Denali Therapeutics in a report on Monday, May 11th. Deutsche Bank Aktiengesellschaft raised their price target on Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Finally, UBS Group boosted their price objective on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Thirteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.92.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Denali Therapeutics during the 2nd quarter valued at $360,759,000. Vanguard Group Inc. raised its holdings in shares of Denali Therapeutics by 8.9% in the fourth quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock worth $215,586,000 after acquiring an additional 1,064,972 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Denali Therapeutics by 28.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock worth $119,766,000 after acquiring an additional 1,615,565 shares during the last quarter. Temasek Holdings Private Ltd lifted its position in shares of Denali Therapeutics by 30.9% in the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock valued at $115,784,000 after acquiring an additional 1,657,142 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Denali Therapeutics by 14.6% in the fourth quarter. State Street Corp now owns 6,263,371 shares of the company’s stock valued at $103,408,000 after acquiring an additional 799,110 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.